November 24, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
OncoTherapy Science, Carna Biosciences, CrystalGenomics to Collaborate in Development of Low-molecular Drug for Cancer
 

Tokyo, Feb 1, 2006 (JCN) - OncoTherapy Science (OTS) announced on February 1 that it has signed a joint research agreement with Carna Biosciences (CARNA) and CrystalGenomics (CG).

The three companies will collaborate in searching low-molecular compounds that inhibit the activities of two different cancer-specific protein kinases possessed by OTS. Specifically, CARNA will be in charge of protein expression, assay formulation and screening while CG will handle virtual screening of compounds, compound library creation and X-ray crystallographic analysis.

Further, using the newly-identified low-molecular compounds, the three companies will strive to develop compound candidates for cancer treatment. The partners will co-own rights to the new compounds, but OTS will be in charge of commercializing them.


By Aki Tsukioka Contributor

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  OncoTherapy Science, Inc. News  
  OncoTherapy Science, Fuso Pharmaceutical Industries Jointly Undertake Phase I Clinical Trial of Anglogenesis Inhibitor OTS102  (Mar 31, 2006)
  OncoTherapy Science, Carna Biosciences, CrystalGenomics to Collaborate in Development of Low-molecular Drug for Cancer  (Feb 1, 2006)
  OncoTherapy Science, BioWa to Collaborate in Antibody Drug Development  (Oct 25, 2005)
  Medical & Biological Laboratories to Start Clinical Trials of Two Different ELISA Reagents for Serological Diagnosis  (June 27, 2005)
  OncoTherapy Science to Start Clinical Trials of OTS102 Angiogenesis Inhibitor  (Apr 5, 2005)
  Onco Therapy Science, Institute for Antibodies Conclude Licensing Agreement for Anticancer Antibody  (Apr 4, 2005)
  OncoTherapy Science (OTS), BioWa to Join Hands in Antibody Drug Development  (Aug 10, 2004)
  MBL, OncoTherapy Science to Establish Joint Venture for Antibody Drug Business  (Aug 4, 2004)



 Recent  Biotech News   
Otsuka Group Establishes New Company; Strengthens Presence in Vending Machine Market (Nov 17, 2014)
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)

More Biotech news...

 Recent  Biotech News   
Otsuka Group Establishes New Company; Strengthens Presence in Vending Machine Market (Nov 17, 2014)
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)

More Biotech news...
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)